

1 **Urinary Volatile Organic Compound Metabolites are Associated with High Blood**
2 **Pressure Among Non-smoking Participants in the National Health and Nutrition**
3 **Examination Survey (2011-2018)**
4

5 **Authors:**

6 Katlyn E. McGraw^{1*} PhD, Arce Domingo-Relloso¹ PhD, Daniel W. Riggs² PhD, Danielle
7 N. Medgyesi¹ MS, Raghav Neupane³ MPH, Jeanette A. Stingone⁴ PhD, Tiffany R.
8 Sanchez¹ PhD
9

10 **Affiliations:**

11 ¹Columbia University Mailman School of Public Health
12 Department of Environmental Health Science
13 722 W 168th St, New York, NY 10032
14

15 ²Christina Lee Browne Envirome Institute
16 University of Louisville
17 322 W Muhammad Ali Blvd, Louisville, KY 40202
18

19 ³Dr. Kiran C. Patel College of Osteopathic Medicine
20 Nova Southeastern University
21 3200 S University Dr, Fort Lauderdale, FL 33328
22

23 ⁴ Columbia University Mailman School of Public Health
24 Department of Epidemiology
25 722 W 168th St, New York, NY 10032
26
27

28 *** Correspondence:**

29 Katlyn E. McGraw, PhD
30 Columbia University Mailman School of Public Health
31 Department of Environmental Health Science
32 722 W 168th St, New York, NY 10032
33 Tel: 212-305-4596
34 Email: kem2240@cumc.columbia.edu
35
36

37 **Short title:** VOC Exposure and Blood Pressure NHANES 2011-2018
38

39 **Word count:** 7,851
40

41 **Keywords:**

42 Volatile organic compounds, blood pressure, mixtures, acrolein, butadiene
43

44 **ABSTRACT**

45 Background: Volatile organic compounds (VOCs) are ubiquitous environmental
46 pollutants. Exposure to VOCs is associated with cardiovascular disease (CVD) risk
47 factors, including elevated blood pressure (BP) in susceptible populations. However,
48 research in the general population, particularly among non-smoking adults, is limited.
49 We hypothesized that higher VOC exposure is associated with higher BP and
50 hypertension, among non-smokers.

51
52 Methods: We included four cycles of data (2011-2018) of non-smoking adults (n=4,430)
53 from the National Health and Nutrition Examination Survey (NHANES). Urinary VOC
54 metabolites were measured by ultra-performance liquid chromatography–mass
55 spectrometry, adjusted for urine dilution, and log-transformed. We estimated mean
56 differences in BP using linear models and prevalence ratio of stage 2 hypertension
57 using modified Poisson models with robust standard errors. Models were adjusted for
58 age, sex, race and ethnicity, education, body mass index, estimated glomerular filtration
59 rate and NHANES cycle.

60
61 Results: Participants were 54% female, with a median age of 48 years, 32.3% had
62 hypertension, and 7.9% had diabetes. The mean differences (95% CI) in systolic BP
63 were 1.61 (0.07, 3.15) and 2.46 (1.01, 3.92) mmHg when comparing the highest to
64 lowest quartile of urinary acrolein (CEMA) and 1,3-butadiene (DHBMA) metabolites.
65 The prevalence ratios (PR) for hypertension were 1.06 (1.02, 1.09) and 1.05 (1.01,

66 1.09) when comparing the highest to lowest quartiles of urinary acrolein (CEMA) and
67 1,3-butadiene (DHBMA), respectively.

68

69 Conclusions: Exposure to VOCs may be relevant yet understudied environmental
70 contributors to CVD risk in the non-smoking, US population.

71 **NON-STANDARD ABBREVIATIONS AND ACRONYMS**

72 3HPMA – N-Acetyl-S-(3-hydroxypropyl)-L-cysteine

73 BMI – Body mass index

74 BKMR – Bayesian Kernel Machine Regression

75 BP – Blood pressure

76 CEMA – N-Acetyl-S-(2-carboxyethyl)-L-cysteine

77 CI – Confidence intervals

78 CVD – Cardiovascular disease

79 DBP – Diastolic blood pressure

80 DHBMA – N-Acetyl-S-(3,4-dihydroxybutyl)-L-cysteine

81 eGFR – Estimated glomerular filtration

82 HDL – High density lipoprotein cholesterol

83 HPMMA – N-Acetyl-S-(3-hydroxypropyl-1-methyl)-L-cysteine

84 MA – Mandelic acid

85 MHBMA3 – N-Acetyl-S-(4-hydroxy-2-butenyl)-L-cysteine

86 MU – t,t-Muconic Acid

87 NHANES – National Health and Nutrition Examination Survey

88 PGA – Phenylglyoxylic acid

89 PIPs – Posterior inclusion probabilities

90 PMA – N-Acetyl-S-(phenyl)-L-cysteine

91 SBP – Systolic blood pressure

92 VOCs – Volatile organic compounds

93

94 **INTRODUCTION**

95 Volatile organic compounds (VOCs) are an under regulated class of chemicals
96 characterized by low molecular weight and high vapor pressure, properties which lead
97 to rapid vaporization in ambient air.¹⁻⁴ Ambient VOCs are critical in the formation of
98 harmful secondary air pollutants such as ozone and PM_{2.5}.^{5, 6} However, VOCs emitted
99 directly from sources are just as harmful and include tobacco smoke, vehicle exhaust,
100 industrial solvents, manufacture of consumer goods, and oil and gas refining.^{7, 8} Indoor,
101 VOC levels can be up to ten times higher than ambient VOC levels.⁸ Additionally, some
102 VOCs are produced endogenously through processes like lipid peroxidation, glycation,
103 and amino acid oxidation.⁹⁻¹¹ Therefore, VOCs are ubiquitous environmental
104 exposures.

105

106 Urinary biomarkers of VOC exposure provide proximal, personal-level assessments of
107 all routes of exposure to VOCs, including ambient, indoor, and endogenous sources.
108 VOC metabolites from human biomonitoring have been associated with physician-
109 diagnosed cardiovascular disease (CVD),¹² metabolic syndrome,¹³ CVD risk factors,¹⁴⁻¹⁷
110 and ischemic heart disease mortality,¹⁸ particularly for acrolein, benzene, 1,3-butadiene,
111 crotonaldehyde, and styrene. However, these studies identified associations in small,

112 geographically homogenous cohorts, and in CVD-susceptible populations, including
113 individuals who smoke. The relation between VOC biomarkers and blood pressure
114 among non-smoking adults has not yet been elucidated in a large, representative
115 sample of the U.S. population, such as the National Health and Nutrition Examination
116 Survey (NHANES).

117
118 In this study, we evaluated the association between participants' VOC metabolite levels
119 in urine with measured blood pressure (BP) levels and hypertension defined as systolic
120 BP \geq 140 mmHg, diastolic BP \geq 90 mmHg, or self-reported use of BP medications¹⁹ using
121 data from a representative sample of the non-smoking U.S. adult population
122 participating in NHANES from 2011-2018. We hypothesized that exposure to VOCs,
123 specifically urinary metabolites of acrolein, benzene, 1,3-butadiene, crotonaldehyde,
124 and styrene, would be associated with higher BP levels and prevalence of hypertension.
125 Additionally, we conducted an exploratory assessment of all urinary VOC metabolites
126 measured in NHANES and mixtures of urinary VOC metabolites.

127 **METHODS**

128 *Study Population*

129 Led by the National Center for Health Statistics (NCHS) at the Centers for Disease
130 Control and Prevention, NHANES is a series of continuous surveys designed to assess
131 the health and nutritional status of adults and children in the U.S. NHANES is designed
132 as a multiyear, stratified, clustered four-stage sample of noninstitutionalized civilians
133 with fixed sample-size targets for sampling domains defined by age, sex, race and
134 ethnicity, and socioeconomic status, with data released in 2-year cycles. Participants

135 gave informed consent of the survey process and their rights as a participant, and the
136 survey was approved by the NCHS Review Board.²⁰ Questionnaires were administered
137 in-home followed by standardized health examinations in specially equipped mobile
138 examination centers. Deidentified and detailed health datasets are publicly available on
139 the NHANES website.²¹ We combined NHANES data from four cycles (2011-2018) to
140 create a larger and more geographically diverse sample, including all cycles with
141 available data on BP and urinary VOC metabolites.

142

143 *Exclusion Criteria*

144 Of the 39,156 NHANES participants from 2011-2018 combined, 23,825 were 18 years
145 of age and older. We focused on adults because blood pressure varies in childhood and
146 adolescence. There were 7,626 participants with measured urinary VOC metabolites
147 and BP examination data because 1/3 subsample at each cycle are analyzed for
148 environmental chemicals. Because tobacco smoke is a primary source of VOC
149 exposure, self-reported cigarette smoking, and serum cotinine data were used to
150 determine smoking status. We excluded 1,405 individuals who reported currently
151 smoking cigarettes, an additional 451 individuals with serum cotinine levels >10 µg/L,
152 reflecting recent nicotine exposure, and 480 missing self-reported cigarette smoking
153 status or cotinine data, for a final sample of 5,290 non-smoking participants. We further
154 excluded an additional 860 participants with missing data, including 492 missing priority
155 urinary VOCs, 172 missing systolic blood pressure (SBP), 11 missing diastolic blood
156 pressure (DBP), 81 missing urine creatinine, 42 missing BMI, 35 missing diabetes
157 status, 21 missing estimated glomerular filtration rate (eGFR), 3 missing triglycerides

158 (TG), 2 missing high density lipoproteins (HDL), and 1 missing education, for a total of
159 4,430 participants included in our analysis (Figure S1).

160

161 *Urinary VOC Metabolites*

162 Urine specimens were collected at mobile examination centers, frozen at -20°C, and
163 shipped to the Division of Environmental Health Laboratory Sciences, National Center
164 for Environmental Health for analysis.²² Ultra-performance liquid chromatography
165 coupled with electrospray tandem mass spectrometry was used to measure 35 VOC
166 metabolites of 20 parent compounds in urine in nanograms per milliliter (ng/mL).²³

167

168 We report results for 5 hypothesized, priority parent VOCs and their 9 associated
169 urinary metabolites: acrolein (CEMA – N-Acetyl-S-(2-carboxyethyl)-L-cysteine
170 and 3HPMA – N-Acetyl-S-(3-hydroxypropyl)-L-cysteine), benzene (MU – t,t-Muconic
171 Acid and PMA – N-Acetyl-S-(phenyl)-L-cysteine), 1,3-butadiene (DHBMA – N-Acetyl-S-
172 (3,4-dihydroxybutyl)-L-cysteine and MHBMA3 – N-Acetyl-S-(4-hydroxy-2-butenyl)-L-
173 cysteine), crotonaldehyde (HPMMA – N-Acetyl-S-(3-hydroxypropyl-1-methyl)-L-
174 cysteine), and styrene (PGA – N-Acetyl-S-(phenyl)-L-cysteine and MA – Mandelic
175 acid). PGA and MA are metabolites of ethylbenzene and styrene. See Table S1 for all
176 parent compounds, long and short metabolite names, NHANES cycle availability, and
177 limits of detection (LOD). Values below the LOD were imputed with the $LOD/\sqrt{2}$.

178 Although the benzene metabolite, MU, was only available for one cycle (2017-2018,
179 n=1,046), we included MU in primary analyses for comparison to the other benzene
180 metabolite available at the other three cycles, PMA (2011-2016, n=3,207). To correct for

181 urine dilution, we divided all urinary VOC metabolites by urine creatinine and reported
182 levels as nanogram of VOC metabolite per milligrams of creatinine (ng/mg).

183

184 *Blood Pressure and Hypertension*

185

186 BP measurements were collected at mobile examination centers using a

187 sphygmomanometer and appropriately sized cuff for the participant's arm

188 circumference. Three BP readings were collected after five minutes of seated rest. A

189 fourth measurement was collected if a measurement was interrupted or incomplete. All

190 recorded measurements of SBP and DBP were averaged and used as continuous

191 outcome variables.

192

193 For hypertension, our primary endpoint was defined by having either a mean SBP ≥ 140

194 mmHg, a mean DBP ≥ 90 mmHg, or self-reported use of BP medications, also known

195 as stage 2 hypertension.¹⁹ We also conducted sensitivity analyses using two alternate

196 definitions: 1) stage 1 hypertension, where participants were hypertensive if mean SBP

197 ≥ 130 mmHg, mean DBP ≥ 80 mmHg, or were taking BP medications, and 2) if

198 individuals self-reported physician-diagnosed hypertension.

199

200 *Covariates*

201 Age, sex, race and ethnicity, education, and household income were acquired from self-

202 reported questionnaires. Race and ethnicity were classified as Mexican American,

203 Other Hispanic, Non-Hispanic White, Non-Hispanic Black, Non-Hispanic Asian, and

204 Other Races, including multiple races. We reclassified education as less than a high

205 school education, a high school education or GED equivalent, some college, or
206 bachelor's degree or more. Household income categories were reduced to \$0-\$24,999,
207 \$25,000-\$54,999, \$55,000-\$74,999, and \geq \$75,000. Body mass index (BMI, kg/m²) was
208 collected during examination at mobile examination center. Estimated glomerular
209 filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology
210 Collaboration equation,²⁴ which estimates GFR for age, sex, and serum creatinine in
211 μ mol/L. The eGFR can influence metabolite excretion in urine and was therefore used
212 for adjustment in our models. Total cholesterol and high-density lipoprotein (HDL)
213 cholesterol were measured in blood collected at mobile examination centers. Diabetes
214 status was determined based on self-reported responses that the participant was ever
215 told by a doctor they had diabetes or were taking medications to lower blood sugar.
216 Prevalent CVD status was determined based on self-reported responses that the
217 participant was ever told by a doctor they had congestive heart failure, coronary heart
218 disease, angina or angina pectoris, heart attack, or stroke.

219

220 *Statistics*

221 Combined NHANES survey cycles and weights produce estimates representative of the
222 U.S. civilian noninstitutionalized population at the midpoint of the combined survey
223 period. We constructed new sample weights for the combined cycles (4 cycles, 2011-
224 2018) by multiplying 2-year subsample weights for environmental chemicals by 1/4 (for
225 4 NHANES cycles) as described.²⁵

226

227 To characterize our study population, we stratified by hypertension status and
228 continuous and categorical variables of interest using t-tests and χ^2 tests. We used
229 linear regression models for normally distributed BP and modified Poisson regression
230 with robust standard errors for dichotomous hypertension outcomes to estimate
231 prevalence ratios of hypertension.²⁶ Urine VOC metabolite levels were modeled as: (1)
232 quartiles (to compare each of the highest three quartiles to the lowest quartile), (2) per
233 interquartile range (IQR) on log-transformed levels (to compare the 75th to the 25th
234 percentile), and (3) log-transformed levels with restricted quadratic splines (to evaluate
235 the flexible dose-response relationship). Because NHANES represents a younger, more
236 general population, we chose to adjust for sociodemographic factors age, sex, race and
237 ethnicity, education, eGFR, and NHANES cycle year and BMI in our main model, Model
238 1, as to not adjust away potential mediating CVD risk factors based on literature reviews
239 for BP and hypertension.^{27, 28} In Model 2, we further adjust for traditional CVD risk
240 factors including total cholesterol, HDL, triglycerides, diabetes status, and BP
241 medications. We present 9 priority urinary VOC metabolites of parent VOCs acrolein,
242 benzene, 1,3-butadiene, crotonaldehyde, and styrene, from Model 1, in the main text.
243 Model estimates are population weighted mean differences in BP or population
244 weighted prevalence ratio of hypertension with 95% confidence intervals (CI). All central
245 tendency estimates, proportions and effect estimates are population weighted.

246

247 *Secondary analyses*

248 In secondary analyses, we examined the other 12 VOC metabolites measured in
249 NHANES. We used Wald tests and conducted subgroup analysis to assess effect
250 modification by subgroups of age, sex, and race and ethnicity.

251
252 To address potential co-pollutant exposure and collinearity, we used hierarchical
253 Bayesian Kernel Machine Regression (BKMR). Because BKMR cannot account for
254 complex survey weighting, we consider these exploratory analyses. BKMR is a kernel-
255 regression based machine learning method that characterizes the exposure response
256 function of multiple predictors on a health outcome while other predictors are fixed to a
257 specific percentile.^{29, 30} The method also allows us to examine statistical interactions
258 between VOC metabolites within the mixture and joint associations between the whole
259 mixture and health outcomes. The hierarchical BKMR uses hierarchical variable
260 selection to create posterior inclusion probabilities (PIPs) that quantify the relative
261 importance by selecting 1) at the group level and 2) by selecting exposures of each
262 group.²⁹ All metabolites with the same parent compound were grouped in hierarchical
263 analysis except for MHBMA3 and HPMMA which were more highly correlated than
264 DHBMA and MHBMA3 (Figure S2). We excluded the benzene metabolites, MU and
265 PMA, due to missing cycles. BKMRs were run with 10,000 iterations and the tuning
266 parameter r_{jump} value of 0.1 for continuous SBP and DBP and dichotomous
267 hypertension to achieve higher acceptance rates.

268 269 *Sensitivity Analyses*

270 We conducted several sensitivity analyses. Because a number of participants reported
271 use of BP lowering medications, we assessed differences between measured and

272 underlying BP.³¹ For individuals self-reporting use of BP lowering medications we
273 imputed underlying BP values by adding a 10 mm Hg or 5 mm Hg constant to measured
274 SBP or DBP, respectively.³¹ Additionally, we assessed differences between Stage 1,
275 Stage 2, and physician-diagnosed hypertension.

276
277 Data analysis was performed in R (version 3.1.3)³² using the nhanesA³³, tidyverse³⁴ and
278 survey package³⁵ to account for the complex survey design and sampling weights.

279

280 **RESULTS**

281 The characteristics of NHANES participants by hypertension status are shown in Table
282 1. Participants were 54% female, with a median age of 48 years, 32.3% had
283 hypertension, and 17.9% had diabetes mellitus. Participants with hypertension were
284 older and more likely to be non-Hispanic White or non-Hispanic Black, had higher BMI,
285 lower eGFR, lower HDL cholesterol, higher triglycerides, higher total cholesterol, and
286 were more likely to have self-reported physician diagnosed CVD and diabetes mellitus.
287 Additionally, participants with hypertension had higher median levels of all priority
288 urinary VOC metabolites compared to participants without hypertension (Table 2 and
289 Table S2), except for the PMA benzene metabolite.

290

291 Results for priority VOC metabolites and BP outcomes are shown in Table 3. For
292 acrolein, the urinary metabolite CEMA was associated with higher SBP and a higher
293 prevalence of hypertension. When comparing the highest to lowest quartile, the mean
294 difference (MD) (95%CI) was 1.61 (0.07, 3.15) mmHg for SBP, and the prevalence ratio

295 (PR) (95%CI) of hypertension was 1.06 (1.02, 1.09). Estimates for SBP and
296 hypertension were also statistically significant per log IQR-change and, although
297 attenuated, generally remained significant after further adjustment for CVD risk factors.
298 In the restricted quadratic spline models, there were clear positive dose-response
299 relationships with SBP and PR of hypertension observed for CEMA above 34.20 ng/mg
300 creatinine (Figures 1 and 2). For the other acrolein metabolite, 3HPMA, results were
301 positive but not significant for SBP (MD [95%CI]: 1.28 [-0.33, 2.90] mmHg); however,
302 the association with hypertension was statistically significant (PR [95%CI]: 1.05 [1.01,
303 1.09]).

304
305 Likewise, for 1,3-butadiene, the urinary metabolite DHBMA was associated with higher
306 SBP and a higher prevalence of hypertension. When comparing the highest to lowest
307 quartile of DHBMA, the MD in SBP was 2.46 (1.01, 3.92) mmHg and the PR of
308 hypertension was 1.05 (1.01, 1.09). Estimates for SBP and hypertension were also
309 statistically significant per log IQR-change and, although attenuated, generally remained
310 significant after further adjustment for CVD risk factors. The linear association apparent
311 in the quartile models was also observed with the restricted quadratic spline models,
312 with clear positive dose-response relationships with SBP and PR of hypertension
313 observed for DHBMA above 252 ng/mg creatinine (Figures 1 and 2). For the other 1,3-
314 butadiene metabolite, MHBMA3, results were less consistent, but there was an
315 association with hypertension per log IQR of MHBMA3 (PR [95%CI]: 1.01 [1.00, 1.02]).

316

317 For the other priority metabolites, results were less consistent. The benzene metabolite,
318 MU, was associated with higher SBP per log IQR of MU (MD [95%CI]: 0.76 [0.05, 1.48]
319 mmHg), but not with higher prevalence of hypertension. When comparing the highest
320 quartile to the lowest quartile, the crotonaldehyde metabolite, HPMMA, and the styrene
321 metabolite, MA, were associated with higher prevalence of hypertension (PR [95%CI]:
322 1.06 [1.02, 1.10], and 1.05 [1.01, 1.08]), respectively. Estimates for HPMMA and MA
323 and SBP trended positive but were not statistically significant. Additionally, we found no
324 significant results for any of the priority VOC metabolites and DBP (Table 3 and
325 Figure S3). Results for the other urinary VOC metabolites available in NHANES (i.e.,
326 parent compounds: acrylamide, acrylonitrile, 1-bromopropane, carbon disulfide,
327 cyanide, n,n-dimethylformamide, isoprene, propylene oxide, toluene, and xylene) are
328 reported in Table S3.

329

330 In Wald tests for interaction, we found significant interactions between age and all
331 priority VOC metabolites except for the benzene metabolite PMA (Table S4).

332 In models stratified by age groups for priority VOCs, the associations with SBP were
333 stronger for the age subgroup 40-64 for metabolites of benzene (MU), 1,3-butadiene
334 (DHBMA), and styrene (PGA). For hypertension, associations were stronger for the age
335 group 40-64 and ≥ 65 for metabolites of acrolein (CEMA) and crotonaldehyde (HPMMA),
336 the age group 40-64 for the metabolites of benzene (MU) and styrene (PGA), and the
337 age group ≥ 65 for metabolites of 1,3-butadiene (MHBMA3) and styrene (MA). We found
338 significant interactions between sex and metabolites of acrolein, 1,3-butadiene, and
339 crotonaldehyde. By sex, the association with SBP was stronger in females for

340 metabolites of acrolein (CEMA, 3HPMA), 1,3-butadiene (DHBMA) and crotonaldehyde
341 (HPMMA). We found significant interactions between race and ethnicity for all VOC
342 metabolites except for the benzene metabolite PMA and the styrene metabolite PGA.
343 The association with SBP was stronger for Mexican Americans for 1,3-butadiene
344 (DHBMA), for Non-Hispanic Asians for acrolein (CEMA), and for Non-Hispanic Blacks
345 for styrene (MA). The association with hypertension was stronger for Non-Hispanic
346 Whites for metabolites of acrolein (3HPMA), benzene (MU), crotonaldehyde (HPMMA)
347 and styrene (MA). Patterns for other VOCs were inconsistent.

348
349 In sensitivity analyses, we found that effect sizes of associations with underlying BP
350 were consistent with the main analyses of original, measured BP (data not shown).
351 Similarly, the use of Stage 2 or physician diagnosed definitions of hypertension did not
352 significantly change effect sizes; however, use of stage 1 hypertension outcome
353 attenuated associations, except for the styrene metabolite (MA) (Figure S4).

354
355 Urinary VOC metabolites originating from the same parent compound were highly
356 correlated except for 1,3-butadiene metabolites, where MHBMA3 was more highly
357 correlated with crotonaldehyde metabolite, HPMMA (Figure S2). We found no
358 significant association between the VOC metabolite mixture and SBP (Figure S5).
359 However, the VOC mixture and overall risk of hypertension was significant and positive.
360 Conditional posterior inclusion probabilities were higher for acrolein metabolite, CEMA,
361 and 1,3-butadiene metabolite, DHBMA, for SBP and CEMA for hypertension (Table S5).

362

363 **DISCUSSION**

364 In this nationally representative study of non-smoking adults, we found that the acrolein
365 metabolite, CEMA, and the 1,3-butadiene metabolite, DHBMA, were consistently and
366 significantly associated with higher SBP and higher prevalence of hypertension in
367 quartile, log IQR, and restricted spline models. The other priority VOC metabolites were
368 less consistent across BP outcomes. Estimates were attenuated after adjustment for
369 cardiovascular risk factors. Exploratory hierarchical BKMR analyses supported acrolein
370 and 1,3-butadiene as important contributors to SBP and hypertension risk and the
371 overall mixture of VOC metabolites (excluding benzene) was associated with
372 hypertension.

373
374 Elevated BP is an important risk factor for the development of CVD and is associated
375 with the highest population attributable fraction for CVD deaths in the U.S. (40.6%).³⁶
376 Systolic hypertension is usually the result of arterial thickening and stiffening caused
377 either by atherosclerosis, medial degradation, or impaired endothelial-mediated
378 vasodilation,³⁷ processes that have been shown to be sensitive to VOCs in experimental
379 studies.^{14, 38} Taken together, these observations suggest that exposure to VOCs,
380 particularly acrolein and 1,3-butadiene, may be significant contributors to the
381 development of CVD, in the general non-smoking population.

382
383 Among NHANES 2011-2018 participants the acrolein metabolite, CEMA, was
384 associated with higher SBP and prevalence of hypertension and the 3HPMA metabolite
385 was associated with higher prevalence of hypertension. Acrolein is a pesticide,

386 combustion byproduct, precursor in the production of other chemicals, and byproduct of
387 lipid peroxidation, glycation, and amino acid oxidation; 3HPMA and CEMA account for
388 about 30% of the dose from exposure.³⁹ Epidemiological evidence shows acrolein
389 metabolites are associated with SBP among nonsmoking adults, including in a cohort of
390 308 adults in Louisville, KY of mean age 51.7 years (MD [95%CI] CEMA: 1.2 [-0.3, 3.3]
391 mmHg and 3HPMA: 0.98 [0.04, 1.9] mmHg)¹⁴ and a cohort of 778 Black participants in
392 Jackson, MS of mean age 51.3 years (CEMA: 1.6 [0.4, 2.7] mmHg and 3HPMA: 0.8
393 [0.01, 1.6] mmHg).⁴⁰ However, associations between acrolein metabolites and
394 hypertension were null among participants in Jackson, MS. A 2022 analysis of ambient
395 VOC exposure in the Sister Study (n=47,467) found that ambient acrolein exposure was
396 associated with a greater risk of hypertension, particularly among never smoking
397 women 35-74 years of age.⁴¹ Likewise, in a nested case-cohort study of non-smoking
398 individuals in northeastern Iran (n=1,198), there was an increased hazard ratio of
399 ischemic heart disease mortality associated with metabolites of acrolein (CEMA, 2.11
400 (1.31, 3.40) and 3HPMA, 2.99 (1.60, 5.59)) when comparing the highest tertile to the
401 lowest.¹⁸

402

403 In this study, we also found the 1,3-butadiene metabolite, DHBMA, was positively
404 associated with higher SBP and greater risk of hypertension, and MHBMA3 was
405 associated with higher prevalence of hypertension. Most human exposure from 1,3-
406 butadiene occurs from incomplete combustion of fossil fuels and burning of biomass.⁴²
407 DHBMA is the most abundant metabolite in urine due to its natural background, which
408 may be caused by endogenous sources.^{43, 44} It is unknown whether high background

409 levels of DHBMA are due to 1,3-butadiene exposures or endogenous sources like lipid
410 peroxidation. Additionally, crotonaldehyde is produced endogenously from the
411 metabolism of 1,3-butadiene and may contribute to higher levels of DHBMA.⁴⁵⁻⁴⁷
412 Although MHBMA3 is a sensitive marker of 1,3-butadiene exposure, DHBMA is not a
413 sensitive marker,⁴⁸ and does not decrease with smoking cessation, compared to
414 MHBMA3.⁴⁹ Therefore, DHBMA may be a relevant biomarker for CVD risk,⁵⁰ but may
415 not be indicative of 1,3-butadiene exposure. In the Sister Study (n=47,467), ambient
416 1,3-butadiene at the census tract level was associated with 1.05 (95% CI 1.00, 1.10)
417 greater risk of hypertension.⁴¹ Additionally, there was a higher ischemic heart disease
418 mortality hazard ratio associated with 1,3-butadiene [DHBMA, 2.49 (1.50, 4.15)] in a
419 recent study of non-smoking northeastern Iranians (n=1,198).¹⁸ However, associations
420 were null among participants in the Louisville, KY and Jackson, MS studies.^{14, 40} More
421 studies of low-level 1,3-butadiene exposures are required to better assess the
422 sensitivity of DHBMA as an exposure biomarker.

423
424 The other priority metabolites were associated with either higher SBP or higher
425 prevalence of hypertension, but not both. The benzene metabolite, MU (but not PMA),
426 was associated with higher SBP. This may be due to smaller sample size compared
427 with the other VOC metabolites. Limited, consistent evidence exists of urinary benzene
428 metabolites and ambient benzene and cardiovascular outcomes due to ongoing
429 analytical issues.^{51, 52} In the Sister Study, ambient benzene was significantly associated
430 with a 1.06 (95% CI 1.01, 1.10) greater risk of hypertension among never smokers.⁴¹
431 The crotonaldehyde metabolite, HPMMA, was associated with higher prevalence of

432 hypertension. Among nonsmoking Black participants in Jackson, MS, HPMMA was
433 associated with higher SBP (MD: 1.2 [95%CI: 0.08, 1.8] mm Hg),⁴⁰ but associations with
434 hypertension were null. Similarly, results for HPMMA and BP were null in the Louisville,
435 KY cohort.¹⁴ The styrene metabolite, MA (but not PGA), was associated with higher
436 prevalence of hypertension. Consistent with our results, the Consortium of Safe Labor
437 showed that ambient styrene was associated with greater odds of hypertension and
438 higher SBP and DBP among normotensive women.^{53, 54} Additionally, two longitudinal
439 studies of occupational co-exposure to 1,3-butadiene and styrene have shown
440 increased standardized mortality ratios for arteriosclerotic heart disease in non-White
441 populations;⁵⁵⁻⁵⁷ there was no data on only styrene exposure. However, in the recent
442 case-cohort study in Iran, there was an increased risk of ischemic heart disease
443 mortality associated with both metabolites of styrene [MA, 1.94 (1.18, 3.20) and PGA,
444 1.54 (1.00, 2.37)].¹⁸

445
446 *Limitations & Future Direction*

447 This large study of VOC metabolites and blood pressure in a representative population
448 of U.S. adults included 4,430 nonsmoking participants and evaluated 35 different VOC
449 metabolites in urine. To minimize error from multiple testing, we prioritized nine VOC
450 metabolites from five parent VOCs, acrolein, benzene, 1,3-butadiene, crotonaldehyde,
451 and styrene, based on prior evidence. All VOC metabolites with >50% observations
452 above LOD available in NHANES, however, were explored in secondary analyses.
453 Previous studies have measured VOCs in air and grouped them by structure, functional
454 group, or as a measure of total VOCs; here, we used stable urinary metabolites of VOC
455 exposure, a robust measure of short-term exposure. The existing literature has been

456 limited by the sample size of non-smokers with measured VOC metabolites. By
457 combining 4 cycles of NHANES we increased the non-smoking sample size resulting in
458 the largest study of VOC metabolites and BP among the general, non-smoking US
459 population. Because metabolites from the same parent VOCs are highly correlated, we
460 used hierarchical BKMR to confirm single-pollutant models after taking correlated VOC
461 co-exposures into account, as well as determined the effects of VOC mixtures on BP
462 and hypertension. These mixture analyses were only exploratory as a weighting
463 scheme for complex survey designs has not yet been developed for BKMR.

464
465 Other limitations include the cross-sectional design and potential for exposure
466 misclassification. Data from other cohorts designed to study cardiovascular health, like
467 the Multi-Ethnic Study of Atherosclerosis, may help elucidate differences in
468 cardiovascular risk among VOC exposure groups, particularly with a longitudinal design
469 to evaluate changes in BP levels and hypertension risk over time.

470 **PERSPECTIVES**

471
472 This study in NHANES found that metabolites of acrolein and 1,3-butadiene were
473 associated with higher SBP and risk of hypertension, in the non-smoking, general US
474 population. Additional research is needed to characterize the contribution of non-
475 smoking related environmental VOC exposures to cardiovascular risk and to develop
476 policy and interventions to curb preventable exposure to VOCs and further reduce the
477 risk of CVD.

478

479 **NOVELTY AND RELEVANCE**

480 What is New?

- 481 • This is the largest biomonitoring study of VOC exposure and elevated blood
482 pressure in the general, non-smoking U.S. population.
- 483 • VOCs present in the environment and/or endogenous VOCs are associated with
484 higher systolic BP and greater prevalence of hypertension.

485

486 What is Relevant?

- 487 • VOC exposure, independent of cigarette smoking, may contribute to the growing
488 prevalence of cardiovascular diseases

489

490 Clinical/Pathophysiological Implications

- 491 • Reduction of VOC exposure may improve cardiovascular health.

492

493 **ACKNOWLEDGEMENTS**

494 Data and materials produced by Federal agencies are in the public domain and may be
495 reproduced without permission. However, the authors would like to thank participants in
496 the National Health and Nutrition Examination Surveys (NHANES).

497 **SOURCES OF FUNDING**

498 Work in the authors' laboratories is supported by NIEHS grants P42ES023716,
499 P42ES033719, P30ES009089, R01ES029967, and T32ES00732221.

500 **DISCLOSURES**

501 The authors have no conflicts of interest to disclose.

502 **SUPPLEMENTAL MATERIAL**

503 Tables S1-S5
504 Figures S1-S5
505

506 **REFERENCES**

507

508

- 509 1. McDonald BC, de Gouw JA, Gilman JB, Jathar SH, Akherati A, Cappa CD, et al. Volatile
510 chemical products emerging as largest petrochemical source of urban organic emissions.
511 *Science (New York, N. Y.)*. 2018;359:760-764
- 512 2. Landrigan PJ, Fuller R, Acosta NJR, Adeyi O, Arnold R, Basu NN, et al. The lancet commission
513 on pollution and health. *Lancet (London, England)*. 2018;391:462-512
- 514 3. Armor JN. Volatile organic compounds: An overview. *Environmental catalysis*. American
515 Chemical Society; 1994:298-300.
- 516 4. United States Environmental Protection Agency U. Volatile organic compounds emissions. *Report*
517 *on the Environment*.
- 518 5. Jerrett M, Burnett RT, Pope CA, Ito K, Thurston G, Krewski D, et al. Long-term ozone exposure
519 and mortality. *New England Journal of Medicine*. 2009;360:1085-1095
- 520 6. Jimenez JL, Canagaratna MR, Donahue NM, Prevot ASH, Zhang Q, Kroll JH, et al. Evolution of
521 organic aerosols in the atmosphere. *Science (New York, N. Y.)*. 2009;326:1525
- 522 7. Danforth CG, Portier C, Ensor KB, Hopkins L, Evans B, Quist AJL, et al. Development and
523 demonstration of a data visualization platform of short-term guidelines for ambient air levels of
524 benzene during disaster response in houston, tx. *Integrated Environmental Assessment and*
525 *Management*.n/a
- 526 8. U.S. Environmental Protection Agency. Technical overview of volatile organic compounds. *Indoor*
527 *Air Quality*. 2017;2019
- 528 9. Kehrer JP, Biswal SS. The molecular effects of acrolein. *Toxicol Sci*. 2000;57:6-15
- 529 10. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal,
530 malonaldehyde and related aldehydes. *Free Radic Biol Med*. 1991;11:81-128
- 531 11. Uchida K. Role of reactive aldehyde in cardiovascular diseases. *Free Radic Biol Med*.
532 2000;28:1685-1696
- 533 12. Xu X, Freeman NC, Dailey AB, Ilacqua VA, Kearney GD, Talbott EO. Association between
534 exposure to alkylbenzenes and cardiovascular disease among national health and nutrition
535 examination survey (nhanes) participants. *International journal of occupational and environmental*
536 *health*. 2009;15:385-391
- 537 13. Shim YH, Ock JW, Kim Y-J, Kim Y, Kim SY, Kang D. Association between heavy metals,
538 bisphenol a, volatile organic compounds and phthalates and metabolic syndrome. *Int J Environ*
539 *Res Public Health*. 2019;16:671
- 540 14. McGraw KE, Riggs DW, Rai S, Navas-Acien A, Xie Z, Lorkiewicz P, et al. Exposure to volatile
541 organic compounds – acrolein, 1,3-butadiene, and crotonaldehyde – is associated with vascular
542 dysfunction. *Environmental Research*. 2021:110903
- 543 15. McGraw KEaK, Stacey L. and Riggs, Daniel W. and Rai, Shesh N. and DeJarnett, Natasha K.
544 and Xie, Zhengzhi and Keith, Rachel J. and Oshunbade, Adebamike A. and Hall, Michael E. and
545 Shimbo, Daichi and Bhatnagar, Aruni. . Exposure to volatile organic compounds is associated
546 with hypertension in black adults: The jackson heart study. . *Available at SSRN*. 2022
- 547 16. DeJarnett N, Conklin DJ, Riggs DW, Myers JA, O'Toole TE, Hamzeh I, et al. Acrolein exposure is
548 associated with increased cardiovascular disease risk. *Journal of the American Heart*
549 *Association*. 2014;3
- 550 17. Abplanalp W, DeJarnett N, Riggs DW, Conklin DJ, McCracken JP, Srivastava S, et al. Benzene
551 exposure is associated with cardiovascular disease risk. *PLoS one*. 2017;12:e0183602
- 552 18. Nalini M, Poustchi H, Bhandari D, Chang CM, Blount BC, Wang L, et al. Volatile organic
553 compounds and mortality from ischemic heart disease: A case-cohort study. *American Journal of*
554 *Preventive Cardiology*. 2024:100700
- 555 19. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017
556 acc/aha/aapa/abc/acpm/ags/apha/ash/aspc/nma/pcna guideline for the prevention, detection,
557 evaluation, and management of high blood pressure in adults: A report of the american college of
558 cardiology/american heart association task force on clinical practice guidelines. *Hypertension*.
559 2018;71:e13-e115

- 560 20. U.S. Department of Health and Human Services. National health and nutrition examination
561 survey: Plan and operations, 1999-2010. 2013
- 562 21. Centers for Disease Control and Prevention (CDC). National health and nutrition examination
563 survey data. 2011-2018
- 564 22. centers for Disease Control and Prevention (CDC). Laboratory procedure manual. *Antimony,*
565 *Arsenic, Barium, Beryllium, Cadmium, Cesium, Cobalt, Lead, Manganese, Molybdenum,*
566 *Platinum, Strontium, Thallium, Tin, Tungsten, and Uranium.* 2012:63
- 567 23. Centers for Disease Control and Prevention C. Laboratory procedure manual: Volatile organic
568 compound (voc)s metabolites. 2011
- 569 24. Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al. New creatinine- and
570 cystatin c–based equations to estimate gfr without race. *New England Journal of Medicine.*
571 2021;385:1737-1749
- 572 25. Centers for Disease Control and Prevention (CDC). Module 3: Weighting. *National Health and*
573 *Nutrition Examination Survey.* 2022
- 574 26. Zou G. A modified poisson regression approach to prospective studies with binary data. *American*
575 *Journal of Epidemiology.* 2004;159:702-706
- 576 27. Fox ER, Samdarshi TE, Musani SK, Pencina MJ, Sung JH, Bertoni AG, et al. Development and
577 validation of risk prediction models for cardiovascular events in black adults: The jackson heart
578 study cohort. *JAMA Cardiology.* 2016;1:15-25
- 579 28. Forde AT, Sims M, Muntner P, Lewis T, Onwuka A, Moore K, et al. Discrimination and
580 hypertension risk among african americans in the jackson heart study. *Hypertension.*
581 2020;76:715-723
- 582 29. Bobb JF, Valeri L, Claus Henn B, Christiani DC, Wright RO, Mazumdar M, et al. Bayesian kernel
583 machine regression for estimating the health effects of multi-pollutant mixtures. *Biostatistics.*
584 2015;16:493-508
- 585 30. Bobb JF. Bayesian kernel machine regression [r package bkmr
586 version 0.2.0]. 2017
- 587 31. Balakrishnan P, Beaty T, Young JH, Colantuoni E, Matsushita K. Methods to estimate underlying
588 blood pressure: The atherosclerosis risk in communities (aric) study. *PLoS one.*
589 2017;12:e0179234-e0179234
- 590 32. R Core Team. R: A language and environment for statistical computing. *R Foundation for*
591 *Statistical Computing, Vienna, Austria.* 2019
- 592 33. Endres CJ. Nhanesa: Nhanes data retrieval. 2019
- 593 34. Wickham et al. Welcome to the tidyverse. *Journal of Open Source Software.* 2019;4
- 594 35. Lumley T. Complex surveys: A guide to analysis using r: A guide to analysis using r. 2010
- 595 36. Yang Q, Cogswell ME, Flanders WD, Hong Y, Zhang Z, Loustalot F, et al. Trends in
596 cardiovascular health metrics and associations with all-cause and cvd mortality among us adults.
597 *JAMA.* 2012;307:1273-1283
- 598 37. Mitchell GF, Conlin PR, Dunlap ME, Lacourcière Y, Arnold JM, Ogilvie RI, et al. Aortic diameter,
599 wall stiffness, and wave reflection in systolic hypertension. *Hypertension.* 2008;51:105-111
- 600 38. Conklin DJ. Acute cardiopulmonary toxicity of inhaled aldehydes: Role of trpa1. *Annals of the*
601 *New York Academy of Sciences.* 2016;1374:59-67
- 602 39. Stevens JF, Maier CS. Acrolein: Sources, metabolism, and biomolecular interactions relevant to
603 human health and disease. *Molecular nutrition & food research.* 2008;52:7-25
- 604 40. McGraw KE, Konkle SL, Riggs DW, Rai SN, DeJarnett N, Xie Z, et al. Exposure to volatile
605 organic compounds is associated with hypertension in black adults: The jackson heart study.
606 *Environmental Research.* 2023;223:115384
- 607 41. Xu J, Niehoff NM, White AJ, Werder EJ, Sandler DP. Fossil-fuel and combustion-related air
608 pollution and hypertension in the sister study. *Environ Pollut.* 2022;315:120401
- 609 42. Walker VE, Degner A, Carter EW, Nicklas JA, Walker DM, Tretyakova N, et al. 1,3-butadiene
610 metabolite 1,2,3,4 diepoxybutane induces DNA adducts and micronuclei but not t(9;22)
611 translocations in human cells. *Chemico-Biological Interactions.* 2019;312:108797
- 612 43. Boogaard PJ, van Sittert NJ, Megens HJ. Urinary metabolites and haemoglobin adducts as
613 biomarkers of exposure to 1,3-butadiene: A basis for 1,3-butadiene cancer risk assessment.
614 *Chem Biol Interact.* 2001;135-136:695-701

- 615 44. van Sittert NJ, Megens HJ, Watson WP, Boogaard PJ. Biomarkers of exposure to 1,3-butadiene
616 as a basis for cancer risk assessment. *Toxicol Sci.* 2000;56:189-202
- 617 45. Conklin DJ, Ogunwale MA, Chen Y, Theis WS, Nantz MH, Fu X-A, et al. Electronic cigarette-
618 generated aldehydes: The contribution of e-liquid components to their formation and the use of
619 urinary aldehyde metabolites as biomarkers of exposure. *Aerosol Sci Technol.* 2018;52:1219-
620 1232
- 621 46. Grant RL, Jenkins AF. Use of in vivo and in vitro data to derive a chronic reference value for
622 crotonaldehyde based on relative potency to acrolein. *Journal of toxicology and environmental*
623 *health. Part B, Critical reviews.* 2015;18:327-343
- 624 47. National Center for Biotechnology Information. Crotonaldehyde.CID=447466
- 625 48. Carrieri M, Bartolucci GB, Paci E, Sacco P, Pigni D, Zaratin L, et al. Validation of a radial
626 diffusive sampler for measuring occupational exposure to 1,3-butadiene. *Journal of*
627 *Chromatography A.* 2014;1353:114-120
- 628 49. Carmella SG, Chen M, Han S, Briggs A, Jensen J, Hatsukami DK, et al. Effects of smoking
629 cessation on eight urinary tobacco carcinogen and toxicant biomarkers. *Chem Res Toxicol.*
630 2009;22:734-741
- 631 50. Lin C-Y, Lee H-L, Jung W-T, Sung F-C, Su T-C. The association between urinary levels of 1,3-
632 butadiene metabolites, cardiovascular risk factors, microparticles, and oxidative stress products in
633 adolescents and young adults. *Journal of Hazardous Materials.* 2020;396:122745
- 634 51. Tevis DS, Willmore A, Bhandari D, Bowman B, Biren C, Kenwood BM, et al. Large differences in
635 urinary benzene metabolite s-phenylmercapturic acid quantitation: A comparison of five lc-ms
636 methods. *Journal of Analytical Toxicology.* 2020;45:657-665
- 637 52. National Health and Nutrition Examination Survey. Volatile organic compound (voc) metabolites -
638 urine (uvoc_g). *2011-2012 Data Documentation, Codebook, and Frequencies.* 2011-2012
- 639 53. Mannisto T, Mendola P, Liu D, Leishear K, Sherman S, Laughon SK. Acute air pollution exposure
640 and blood pressure at delivery among women with and without hypertension. *Am J Hypertens.*
641 2015;28:58-72
- 642 54. Zhu Y, Zhang C, Liu D, Ha S, Kim SS, Pollack A, et al. Ambient air pollution and risk of
643 gestational hypertension. *Am J Epidemiol.* 2017;186:334-343
- 644 55. Matanoski GM, Santos-Burgoa C, Schwartz L. Mortality of a cohort of workers in the styrene-
645 butadiene polymer manufacturing industry (1943-1982). *Environ Health Perspect.* 1990;86:107-
646 117
- 647 56. Divine BJ, Hartman CM. Mortality update of butadiene production workers. *Toxicology.*
648 1996;113:169-181
- 649 57. Matanoski GM, Tao X. Styrene exposure and ischemic heart disease: A case-cohort study.
650 *American Journal of Epidemiology.* 2003;158:988-995
- 651
- 652

653 **TABLES**

654

655 **Table 1.** Participant characteristics across categories of hypertension, restricted to non-
 656 smoking participants with available blood pressure examination data and urinary VOCs,
 657 n=4,430 NHANES 2011-2018 participants. Continuous variables are reported as
 658 median [interquartile range, IQR] and categorical variables as number (%). Percentages
 659 are population weighted.
 660

	Overall	No Hypertension	Hypertension
n	4,430	2,819	1,611
Age (years)	48 [33, 62]	40 [28, 54]	62 [54, 71]
Sex			
Male	2,044 (46.0)	1,259 (45.3)	785 (47.5)
Female	2,386 (54.0)	1,560 (54.7)	826 (52.5)
Race/Ethnicity			
Mexican American	681 (9.6)	494 (11.3)	187 (6.1)
Other Hispanic	533 (7.3)	369 (8.4)	164 (5.0)
Non-Hispanic White	1,540 (64.8)	943 (62.8)	597 (69.0)
Non-Hispanic Black	868 (9.7)	449 (8.3)	419 (12.6)
Non-Hispanic Asian	679 (6.3)	478 (6.8)	201 (5.2)
Other Race, incl Multi	129 (2.4)	86 (2.5)	43 (2.2)
Education			
Less than HS Diploma	884 (12.2)	500 (11.3)	384 (14.0)
High School Grad/GED	926 (20.7)	553 (19.3)	373 (23.6)
Some College	1,329 (31.1)	841 (30.1)	488 (33.3)
College Degree or More	1,291 (36.0)	925 (39.4)	366 (28.9)
Income			
\$0-\$24,999	1,002 (15.9)	563 (14.6)	439 (18.7)
\$25,000-\$54,999	1,308 (29.1)	828 (29.4)	480 (28.5)
\$55,000-\$74,999	490 (13.1)	335 (13.4)	155 (12.4)
≥\$75,000	1,352 (41.9)	913 (42.7)	439 (40.4)
BMI (kg/m ²)	28.3 [24.5, 33.0]	27.2 [23.7, 31.7]	30.7 [26.6, 35.8]
Serum Cotinine (ng/mL)	0.02 [0.01, 0.05]	0.02 [0.01, 0.05]	0.02 [0.01, 0.04]
eGFR (mL/min/1.73 m ²)	97.6 [82.0, 111.9]	103.3 [88.4, 116.7]	86.2 [68.9, 98.9]
HDL (mg/dL)	53.0 [43.0, 63.0]	53.3 [44.0, 64.0]	50.0 [41.0, 61.0]
Triglycerides (mg/dL)	115.0 [77.0, 176.0]	104.0 [72.0, 165.0]	134.0 [94.0, 206.0]
Total Cholesterol (mg/dL)	186.0 [161.0, 214.0]	185.0 [160.0, 213.0]	191.5 [163.0, 218.0]
SBP (mmHg)	120.0 [110.7, 132.0]	114.7 [107.3, 123.3]	136.0 [124.0, 147.3]
DBP (mmHg)	71.3 [64.7, 78.0]	70.0 [64.0, 76.0]	75.3 [66.7, 84.0]
Underlying SBP (mmHg) ^a	122.0 [111.3, 135.3]	114.7 [107.3, 123.3]	142.7 [133.3, 152.7]
Underlying DBP (mmHg) ^b	72.3 [65.3, 79.3]	70.0 [64.0, 76.0]	79.0 [71.0, 87.0]
Hypertension Stage 1 ^c	2,201 (46.9)	590 (21.5)	1,611 (100.0)
Hypertension MDDX ^d	1,542 (31.2)	216 (7.0)	1,326 (81.9)
CVD ^e	382 (7.6)	100 (3.8)	282 (15.3)

Diabetes Mellitus ^f	439 (7.9)	126 (3.1)	313 (17.9)
BP Medications	1,213 (24.1)	0 (0.0)	1,213 (74.5)

661 ^a Underlying Systolic Blood Pressure: a 10 mmHg constant was added to SBP
662 measurement of NHANES participants who self-report taking BP medications ^b
663 Underlying Diastolic Blood Pressure: a 5 mmHg constant was added to SBP
664 measurement of NHANES participants who self-report taking BP medications
665 ^c Hypertension Stage 1 is defined as mean SBP \geq 130 mmHg, DBP \geq 80 mm Hg, or
666 taking BP medications
667 ^d Hypertension MDDX is defined as physician-diagnosed hypertension
668 ^e CVD is defined if a physician has ever told you have congestive heart failure, coronary
669 heart disease, angina, heart attack, or stroke
670 ^f Diabetes Mellitus is defined if a physician ever told you have diabetes mellitus or self-
671 report of taking diabetes medications
672
673

674 **Table 2.** Median and interquartile ranges of VOC metabolite levels (ng/mg creatinine)
 675 across categories of hypertension, restricted to participants with available blood
 676 pressure examination data and urinary VOCs, among 4,430 NHANES 2011-2018
 677 participants. MU was measured in n=1,046 NHANES 2017-2018 participants and PMA
 678 was measured in n=3,207 NHANES 2011-2016 participants.
 679

Parent	Short ^a	Overall	No Hypertension	Hypertension
		4,430	2,819	1,611
Acrolein	CEMA	82.3 [54.5, 128.2]	76.2 [50.4, 116.7]	96.7 [64.5, 150.4]
Acrolein	3HPMA	193.7 [130.4, 297.6]	189.6 [127.4, 290.0]	202.8 [137.6, 310.8]
Benzene	MU ^b	44.8 [26.8, 93.0]	43.3 [24.5, 93.0]	47.7 [29.0, 93.1]
Benzene	PMA ^c	0.7 [0.5, 1.2]	0.8 [0.4, 1.3]	0.7 [0.5, 1.1]
1,3-Butadiene	DHBMA	300.0 [236.3, 385.1]	288.6 [227.5, 363.5]	340.1 [264.1, 429.8]
1,3-Butadiene	MHBMA3	3.9 [2.6, 6.0]	3.7 [2.5, 5.9]	4.2 [2.9, 6.2]
Crotonaldehyde	HPMMA	185.5 [143.0, 264.6]	173.6 [136.9, 250.0]	212.7 [159.3, 298.8]
Styrene	PGA	197.8 [148.5, 260.4]	190.6 [142.1, 251.0]	214.1 [158.4, 281.3]
Styrene	MA	122.4 [89.5, 164.4]	120.2 [88.9, 159.2]	128.4 [91.9, 172.9]

680 ^a Metabolite long names: CEMA, N-Acetyl-S-(2-carboxyethyl)-L-cysteine; 3HPMA, N-
 681 Acetyl-S-(3-hydroxypropyl)-L-cysteine; PMA, N-Acetyl-S-(phenyl)-L-cysteine; MU, *t,t*-
 682 Muconic Acid; DHBMA, N-Acetyl-S-(3,4-dihydroxybutyl)-L-cysteine; MHBMA3, N-Acetyl-
 683 S-(4-hydroxy-2-butenyl)-L-cysteine; HPMMA, N-Acetyl-S-(3-hydroxypropyl-1-methyl)-L-
 684 cysteine; PGA, Phenylglyoxylic acid; MA, Mandelic acid

685 ^b MU was measured in n=1,046 NHANES 2017-2018 participants, n=604 did not have
 686 hypertension and n=442 did have hypertension

687 ^c PMA was measured in n=3,207 NHANES 2011-2016 participants, n=2,104 did not
 688 have hypertension and n=1,103 did have hypertension

689 **Table 3.** Mean differences (95% confidence interval) of systolic blood pressure (SBP), diastolic blood pressure (DBP),
690 and prevalence ratios – PR (95% confidence interval) of hypertension by levels (ng/mg creatinine) of urinary VOC
691 metabolites, restricted to participants with available blood pressure examination data and urinary VOCs, n=4,430
692 NHANES 2011-2018 participants. MU was measured in n=1,046 NHANES 2017-2018 participants and PMA was
693 measured in n=3,207 NHANES 2011-2016 participants. Model 1 was adjusted for age, sex, race and ethnicity, education,
694 BMI, eGFR, and NHANES cycle year. Model 2 was additionally adjusted for HDL-cholesterol, triglycerides, total
695 cholesterol, diabetes status, and antihypertensive medication.
696

	N	SBP		DBP		Hypertension	
		Model 1	Model 2	Model 1	Model 2	Model 1	Model 2
Acrolein, CEMA							
Q1 (3.64, 56.33)	1,108	0.00 (referent)	0.00 (referent)	0.00 (referent)	0.00 (referent)	1.00 (referent)	1.00 (referent)
Q2 (56.34, 85.00)	1,107	0.24 (-1.19, 1.67)	0.00 (-1.41, 1.41)	0.85 (-0.23, 1.94)	0.63 (-0.48, 1.73)	1.01 (0.98, 1.05)	1.00 (0.98, 1.03)
Q3 (85.06, 128.2)	1,107	0.56 (-1.03, 2.15)	0.09 (-1.38, 1.55)	0.34 (-0.84, 1.52)	-0.07 (-1.20, 1.05)	1.03 (0.99, 1.07)	1.01 (0.98, 1.04)
Q4 (128.3, 4353)	1,108	1.61 (0.07, 3.15)	0.8 (-0.77, 2.37)	0.32 (-0.88, 1.53)	-0.13 (-1.22, 0.95)	1.06 (1.02, 1.09)	1.01 (0.99, 1.03)
p75 vs p25	4,430	0.95 (0.17, 1.73)	0.53 (-0.25, 1.3)	0.15 (-0.37, 0.67)	-0.09 (-0.55, 0.37)	1.03 (1.01, 1.05)	1.00 (1.00, 1.01)
Acrolein, 3HPMA							
Q1 (6.81, 133.33)	1,110	0.00 (referent)	0.00 (referent)	0.00 (referent)	0.00 (referent)	1.00 (referent)	1.00 (referent)
Q2 (133.45, 197.8)	1,105	0.14 (-1.16, 1.43)	-0.11 (-1.41, 1.18)	-0.93 (-2.04, 0.18)	-1.02 (-2.12, 0.09)	1.02 (0.99, 1.05)	1.00 (0.98, 1.02)
Q3 (198.0, 307.2)	1,107	0.56 (-0.98, 2.10)	0.55 (-1.01, 2.12)	-0.77 (-2.00, 0.46)	-0.6 (-1.77, 0.57)	1.02 (0.99, 1.06)	1.01 (0.99, 1.04)
Q4 (307.3, 7947)	1,108	1.28 (-0.33, 2.90)	1.06 (-0.62, 2.74)	-0.34 (-1.76, 1.09)	-0.24 (-1.60, 1.12)	1.05 (1.01, 1.09)	1.02 (0.99, 1.05)
p75 vs p25	4,430	0.41 (-0.31, 1.13)	0.35 (-0.38, 1.09)	-0.18 (-0.80, 0.43)	-0.13 (-0.71, 0.46)	1.02 (1.00, 1.03)	1.00 (0.99, 1.01)
Benzene, MU							
Q1 (6.74, 24.23)	262	0.00 (referent)	0.00 (referent)	0.00 (referent)	0.00 (referent)	1.00 (referent)	1.00 (referent)
Q2 (24.24, 42.54)	261	2.29 (-0.20, 4.78)	1.93 (-0.93, 4.79)	2.50 (0.33, 4.68)	1.95 (-0.32, 4.22)	1.01 (0.92, 1.10)	1.01 (0.96, 1.07)
Q3 (42.77, 84.86)	261	3.29 (-0.25, 6.82)	2.78 (-0.22, 5.79)	1.04 (-1.88, 3.97)	0.36 (-1.97, 2.69)	1.01 (0.92, 1.10)	1.01 (0.95, 1.08)
Q4 (85.14, 9294)	262	2.75 (-0.65, 6.15)	2.36 (-0.74, 5.45)	-1.32 (-4.09, 1.46)	-1.99 (-4.37, 0.39)	1.01 (0.95, 1.08)	1.01 (0.96, 1.07)
p75 vs p25	1,046	0.76 (0.05, 1.48)	0.65 (-0.04, 1.35)	-0.11 (-0.56, 0.35)	-0.28 (-0.65, 0.08)	1.00 (0.98, 1.02)	1.00 (0.99, 1.01)
Benzene, PMA							
Q1 (0.09, 0.420)	809	0.00 (referent)	0.00 (referent)	0.00 (referent)	0.00 (referent)	1.00 (referent)	1.00 (referent)

Q2 (0.424, 0.695)	804	0.73 (-1.26, 2.73)	0.79 (-1.19, 2.77)	0.12 (-1.13, 1.36)	0.42 (-0.84, 1.68)	1.03 (0.98, 1.08)	1.01 (0.97, 1.04)
Q3 (0.70, 1.145)	801	1.09 (-0.80, 2.97)	1.05 (-0.86, 2.96)	0.94 (-0.39, 2.27)	0.98 (-0.28, 2.23)	1.01 (0.97, 1.05)	1.01 (0.98, 1.04)
Q4 (1.146, 13.00)	793	1.44 (-0.60, 3.47)	1.46 (-0.65, 3.57)	0.76 (-0.51, 2.02)	0.95 (-0.29, 2.19)	1.00 (0.96, 1.03)	0.99 (0.96, 1.02)
p75 vs p25	3,207	1.14 (-0.85, 3.13)	1.17 (-0.84, 3.17)	0.77 (-0.37, 1.92)	0.86 (-0.23, 1.96)	1.00 (0.99, 1.01)	1.00 (0.99, 1.01)

1,3-Butadiene, DHBMA

Q1 (2.75, 229.59)	1,108	0.00 (referent)	0.00 (referent)	0.00 (referent)	0.00 (referent)	1.00 (referent)	1.00 (referent)
Q2 (229.62, 294.12)	1,111	1.15 (-0.44, 2.75)	1.08 (-0.45, 2.60)	-0.31 (-1.18, 0.55)	-0.26 (-1.12, 0.60)	1.02 (0.99, 1.05)	1.01 (0.98, 1.03)
Q3 (294.14, 375.0)	1,104	0.84 (-0.74, 2.42)	0.64 (-0.96, 2.25)	0.02 (-1.11, 1.14)	0.06 (-1.08, 1.21)	1.03 (0.99, 1.07)	1.00 (0.98, 1.03)
Q4 (375.29, 3800)	1,107	2.46 (1.01, 3.92)	2.35 (0.91, 3.79)	-0.87 (-2.05, 0.32)	-0.65 (-1.76, 0.46)	1.05 (1.01, 1.09)	1.02 (1.00, 1.05)
p75 vs p25	4,430	2.95 (1.06, 4.85)	2.93 (1.14, 4.72)	-0.49 (-1.94, 0.96)	-0.18 (-1.56, 1.19)	1.01 (1.00, 1.02)	1.01 (1.00, 1.02)

1,3-Butadiene, MHBMA3

Q1 (0.21, 2.636)	1,108	0.00 (referent)	0.00 (referent)	0.00 (referent)	0.00 (referent)	1.00 (referent)	1.00 (referent)
Q2 (2.642, 3.85)	1,110	1.48 (-0.17, 3.12)	1.18 (-0.38, 2.73)	-0.84 (-1.72, 0.04)	-0.91 (-1.76, -0.05)	1.04 (1.01, 1.08)	1.02 (1.00, 1.04)
Q3 (3.86, 5.97)	1,104	-0.14 (-1.76, 1.47)	-0.24 (-1.76, 1.27)	-1.09 (-2.18, 0.01)	-0.96 (-2.00, 0.08)	1.02 (0.99, 1.05)	1.00 (0.98, 1.02)
Q4 (5.98, 328.4)	1,108	0.60 (-0.74, 1.95)	0.51 (-0.87, 1.90)	-0.54 (-1.80, 0.72)	-0.50 (-1.73, 0.73)	1.03 (0.99, 1.06)	1.01 (0.99, 1.04)
p75 vs p25	4,430	0.02 (-0.48, 0.52)	0.01 (-0.50, 0.52)	-0.23 (-0.74, 0.28)	-0.20 (-0.71, 0.30)	1.01 (1.00, 1.02)	1.00 (1.00, 1.01)

Crotonaldehyde, HPMMA

Q1 (1.19, 140.31)	1,108	0.00 (referent)	0.00 (referent)	0.00 (referent)	0.00 (referent)	1.00 (referent)	1.00 (referent)
Q2 (140.32, 185.0)	1,108	1.00 (-0.76, 2.76)	0.63 (-1.20, 2.47)	1.13 (0.03, 2.23)	0.95 (-0.12, 2.03)	1.01 (0.98, 1.05)	0.99 (0.97, 1.02)
Q3 (185.1, 265.85)	1,106	1.25 (-0.19, 2.70)	0.69 (-0.81, 2.19)	0.68 (-0.63, 1.98)	0.64 (-0.67, 1.94)	1.05 (1.02, 1.08)	1.00 (0.98, 1.03)
Q4 (265.91, 10947)	1,108	1.27 (-0.46, 3.00)	0.73 (-1.11, 2.57)	0.3 (-1.14, 1.74)	0.43 (-0.94, 1.81)	1.06 (1.02, 1.10)	1.01 (0.98, 1.04)
p75 vs p25	4,430	0.29 (-0.79, 1.37)	0.10 (-1.02, 1.23)	-0.17 (-1.10, 0.76)	-0.06 (-0.92, 0.79)	1.01 (0.99, 1.02)	1.00 (1.00, 1.01)

Styrene, PGA

Q1 (3.94, 139.39)	1,108	0.00 (referent)	0.00 (referent)	0.00 (referent)	0.00 (referent)	1.00 (referent)	1.00 (referent)
Q2 (139.41, 188.52)	1,107	-1.25 (-3.26, 0.75)	-1.02 (-3.03, 0.99)	-0.70 (-2.07, 0.67)	-0.42 (-1.73, 0.89)	1.00 (0.96, 1.03)	0.99 (0.96, 1.01)
Q3 (188.57, 250.0)	1,116	-0.85 (-2.28, 0.57)	-0.77 (-2.22, 0.67)	-0.36 (-1.78, 1.06)	-0.18 (-1.53, 1.17)	0.99 (0.96, 1.03)	0.99 (0.97, 1.02)
Q4 (250.41, 32525)	1,099	0.24 (-1.85, 2.33)	0.05 (-2.05, 2.16)	-1.02 (-2.51, 0.48)	-1.04 (-2.50, 0.42)	1.02 (0.98, 1.06)	1.01 (0.98, 1.03)
p75 vs p25	4,430	0.34 (-0.73, 1.41)	0.10 (-0.98, 1.18)	-0.18 (-1.08, 0.72)	-0.25 (-1.12, 0.63)	1.00 (0.99, 1.01)	1.00 (0.99, 1.00)

Styrene, MA

Q1 (4.17, 87.61)	1,108	0.00 (referent)	0.00 (referent)	0.00 (referent)	0.00 (referent)	1.00 (referent)	1.00 (referent)
Q2 (87.62, 121.31)	1,107	-0.96 (-2.61, 0.68)	-0.75 (-2.38, 0.89)	-1.47 (-2.62, -0.32)	-1.32 (-2.35, -0.29)	0.99 (0.96, 1.02)	1.00 (0.98, 1.03)
Q3 (121.32, 163.12)	1,107	0.84 (-0.66, 2.34)	0.67 (-0.76, 2.10)	0.23 (-1.12, 1.58)	0.14 (-1.14, 1.42)	1.00 (0.97, 1.03)	1.00 (0.98, 1.03)
Q4 (163.13, 27778)	1,108	1.28 (-0.50, 3.06)	1.12 (-0.63, 2.87)	0.36 (-1.01, 1.73)	0.45 (-0.81, 1.70)	1.05 (1.01, 1.08)	1.03 (1.01, 1.06)
p75 vs p25	4,430	0.85 (-0.33, 2.02)	0.56 (-0.62, 1.74)	0.51 (-0.29, 1.32)	0.48 (-0.25, 1.20)	0.98 (0.95, 1.02)	1.00 (0.97, 1.02)

697


698 Metabolite long names: CEMA, N-Acetyl-S-(2-carboxyethyl)-L-cysteine; 3HPMA, N-Acetyl-S-(3-hydroxypropyl)-L-cysteine;
699 PMA, N-Acetyl-S-(phenyl)-L-cysteine; MU, *t,t*-Muconic Acid; DHBMA, N-Acetyl-S-(3,4-dihydroxybutyl)-L-cysteine;
700 MHBMA3, N-Acetyl-S-(4-hydroxy-2-butenyl)-L-cysteine; HPMMA, N-Acetyl-S-(3-hydroxypropyl-1-methyl)-L-cysteine;
701 PGA, Phenylglyoxylic acid; MA, Mandelic acid

702

703 **FIGURES**

704


705 **Figure 1.** Mean differences (MD) (95% confidence interval) of systolic blood pressure
706 (SBP) by urinary VOC levels (ng/mg creatinine) modeled as restricted quadratic splines
707 for priority VOC metabolites among nonsmoking NHANES 2011-2018 participants
708 (n=4,430). Lines (shaded areas) represent the MD (95%CI) of SBP and RR (95% CI) of
709 hypertension by VOC metabolites modeled as restricted quadratic splines for log
710 transformed VOC metabolite distributions with knots at 10th, 50th, and 90th percentiles.
711 The reference value was set at the 10th percentile. Models were adjusted for age, sex,
712 race and ethnicity, education, BMI, eGFR, and NHANES cycle year. The histograms in
713 the background represent the distribution of each VOC metabolite (ng/mg creatinine).
714 See Figure S2 for DBP.
715



716

717

718 **Figure 2.** Prevalence ratios (PR) (95% confidence interval, CI) of hypertension by
719 urinary VOC levels (ng/mg creatinine) modeled as restricted quadratic splines among
720 nonsmoking NHANES 2011-2018 participants (n=4,430). Lines (shaded areas)
721 represent the PR (95%CI) of hypertension by VOC metabolites modeled as restricted
722 quadratic splines for log transformed VOC metabolite distributions with knots at 10th,
723 50th, and 90th percentiles. The reference value was set at the 10th percentile. Models
724 were adjusted for age, sex, race and ethnicity, education, BMI, eGFR, and NHANES
725 cycle year. The histograms in the background represent the distribution of each VOC
726 metabolite (ng/mg creatinine). See Figure S2 for DBP.
727
728



729
730